4 news items
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHRS
23 May 24
expressed by tumor infiltrating Tregs that suppress the body's natural anti-cancer immune response. Targeting CCR8 is a promising potential therapeutic
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response
Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting
CHRS
8 Apr 24
to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS
8 Apr 24
and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy
- Prev
- 1
- Next